Orexo (ORXO.F) Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ORXO.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.05 |
| 52 Week High | SEK 3.05 |
| 52 Week Low | SEK 1.90 |
| Beta | 0.88 |
| 1 Month Change | 5.17% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -50.00% |
| Change since IPO | -62.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORXO.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | -3.1% |
| 1Y | n/a | 20.1% | 11.2% |
Return vs Industry: Insufficient data to determine how ORXO.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ORXO.F performed against the US Market.
Price Volatility
| ORXO.F volatility | |
|---|---|
| ORXO.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ORXO.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ORXO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 104 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| ORXO.F fundamental statistics | |
|---|---|
| Market cap | US$98.01m |
| Earnings (TTM) | -US$21.30m |
| Revenue (TTM) | US$57.37m |
Is ORXO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORXO.F income statement (TTM) | |
|---|---|
| Revenue | SEK 543.50m |
| Cost of Revenue | SEK 58.70m |
| Gross Profit | SEK 484.80m |
| Other Expenses | SEK 686.60m |
| Earnings | -SEK 201.80m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 05, 2026
| Earnings per share (EPS) | -5.88 |
| Gross Margin | 89.20% |
| Net Profit Margin | -37.13% |
| Debt/Equity Ratio | -210.6% |
How did ORXO.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 00:40 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orexo AB (publ) is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |